VSV Vector Attenuation via Combined Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current VSV vectors exhibit unacceptable levels of residual virulence in small animal and non-human primate neurovirulence models, necessitating the development of genetically modified VSV mutants with significantly reduced or eliminated pathogenicity for safe use in immunogenic compositions and gene therapy.
Innovation Solution
The introduction of combined mutation classes, including temperature-sensitive, point, gene shuffling, G-stem, non-cytopathic M gene, ambisense RNA, truncated G gene, and gene deletion mutations, synergistically attenuates VSV pathogenicity, resulting in a genetically modified VSV vector with enhanced safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If VSV vectors are used for immunogenic compositions and gene therapy, then the ability to replicate robustly and express foreign genes is improved, but residual virulence and pathogenicity in animal models worsen
Solution Approach 1:
The patent applies parameter changes by introducing multiple classes of mutations (temperature-sensitive, point, gene shuffling, G-stem, non-cytopathic M gene, ambisense RNA, truncated G gene, and gene deletion mutations) that alter the viral genome parameters. These mutations collectively reduce the LD50 by at least 100-fold compared to wild-type VSV, thereby changing the virulence parameters while maintaining vector functionality for gene expression and replication.
2Reliability
If multiple mutation classes are introduced to attenuate pathogenicity, then safety profile is improved, but the complexity of vector development and characterization worsens
Solution Approach 1:
The patent applies segmentation by dividing the attenuation strategy into multiple independent mutation classes that can be individually introduced and characterized. Each mutation class (temperature-sensitive, point, gene shuffling, etc.) represents a separate segment of the overall attenuation approach, allowing systematic development and safety assessment of each component before combination.
Data Source
AI summary
The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV). More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.